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Abstract: Background: Functional status assessment is common in many cardiovascular diseases but
it has undergone limited study in the setting of acute heart failure (AHF). Accordingly, we performed
a pilot study of the feasibility of the six-minute walk test (6MWT) at the emergency department
(ED) presentation and through the hospitalization in patients with AHF. Methods and Results:
From November 2014 to February 2015, we conducted a multicenter, observational study of ED
patients, aged 18–85 years, whose primary ED admission diagnosis was AHF. Other criteria for
enrollment included a left ventricular ejection fraction ≤40%, systolic blood pressure between 90 and
170 mmHg, and verbal confirmation that the patient was able to walk >30 m at the baseline, prior to
ED presentation. Study teams were uniformly trained to administer a 6MWT. Patients underwent
a baseline 6MWT within 24 h of ED presentation (Day 1) and follow-up 6MWTs at 24 (Day 2), 48
(Day 3), and 120 h (Day 5). A total of 46 patients (65.2% male, 73.9% African American) had a day one
mean walk distance of 137.3 ± 78 m, day 2 of 170.9 ± 100 m, and day 3 of 180.8 ± 98 m. The 6MWT
demonstrated good reproducibility, as the distance walked on the first 6MWT on Day 3 was similar
to the distance on the repeated 6MWT the same day. Conclusions: Our pilot study demonstrates the
feasibility of the 6MWT as a functional status endpoint in AHF patients. A larger study in a more
demographically diverse cohort of patients is necessary to confirm its utility and association with
30-day heart failure (HF) events.
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1. Background
Quality of life is critical to patients’ health and well-being. While reducing readmissions and
mortality remain important endpoints, maintaining or improving the quality of life may be more
important to patients. For heart failure (HF) patients, some would trade life years for a better
life quality [1]. One key component of quality of life for HF patients is functional ability, such as
maintaining the activities of daily living and self-care.
Functional status assessment is commonly used in chronic HF studies and other cardiovascular
diseases [2]. While subjective symptom assessments are common in acute heart failure (AHF), however,
clinical trials and formal functional status assessment are not [3,4]. Ideally, AHF patients return to
their baseline functional capacity prior to discharge. However, this is seldom rigorously evaluated.
In chronic HF, the 6 min walk test (6MWT) is a validated measure of functional capacity, assessing the
distance a patient can walk in 6 min, performed at the patient’s intrinsic walking speed, including all
patient-determined stops. Changes in 6MWT distance as a result of therapeutic interventions predict
rehospitalizations and mortality [5–7]. However, the feasibility of performing baseline and serial
6MWT in AHF, to assess the potential response to therapy has not been well studied [8]. We performed
a pilot study to determine the feasibility of performing the 6MWT in AHF patients in the emergency
department (ED) and continuing through hospitalization.
2. Methods
Study Design and Setting: From November 2014 to February 2015, we conducted a multicenter
observational study of ED patients, aged 18–85 years, whose primary ED admission diagnosis was
AHF. Patients were enrolled at six academic, urban hospitals in the United States. The study and
all associated procedures were approved by local and/or central IRBs/ethics committees per each
participating institution, and all patients provided written informed consent.
Participants: AHF was established at each institution by the ED provider using history and
physical exam findings, congestion on chest radiograph, and elevated levels of natriuretic peptides. This
diagnosis was confirmed with the treating physician by the study team prior to approaching the patient.
All patients were enrolled within 24 h of ED presentation, though the investigators were encouraged
to approach the patients as soon as AHF was confirmed by the provider. The remaining inclusion
criteria included a left ventricular ejection fraction (LVEF) ≤40% (as assessed by echocardiography,
MRI, MUGA, or right heart catheterization within the 6 months prior to the ED presentation), systolic
blood pressure (SBP) between 90 and 170 mmHg, and verbal confirmation that the patient was able to
walk at least 30 m prior to developing AHF symptoms leading to the index presentation. Patients were
excluded who had other significant non-cardiac limitations to their ambulatory capacity, who were
considered likely to undergo an invasive procedure within three days of study enrollment or who had
eGFR <30 mL/min/1.73 m2 .
Study Procedures: Research teams at all six institutions were uniformly trained by using
standardized methods by study personnel from the Colorado Prevention Center Clinical Research,
a group with extensive prior 6MWT trial experience [9]. Study teams reviewed vital signs and the
most recent laboratories prior to commencing the 6MWT to identify clinically significant changes that
might preclude performance of the 6MWT, such as the orthostatic or new symptomatic systolic blood
pressure less than 90 mmHg. Per eligibility criteria, no patient with a SBP <90 mmHg was allowed to
participate. Furthermore, the investigators were specifically told to exclude patients with any other
significant lab abnormalities that would increase the risk associated with the 6MWT. Oxygen therapy
or walking aids required at baseline were continued in a similar fashion in all subsequent tests for
any given patient. Patients enrolled in the study underwent a baseline (Day 1) 6MWT as early as
possible while in the ED; serial 6MWTs were performed at 24 (Day 2), 48 (Day 3), and 120 h (Day 5;
or at discharge, if sooner) during the patient’s hospital stay. At the 48-h time point, two sequential
6MWTs were performed, separated by a 30-min rest between the tests. Distance to the first stop
was defined as the total distance (meters) walked by the patient before indicating they needed to
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Table 1. Demographics and baseline characteristics of the study cohort.
Parameter
Age

N * (%)

Mean (SD)

48

55.6 (13.0)

Gender
Male

32 (67)

Female

16 (33)

Race
White

13 (27)

Black/African-American

35 (73)

Primary HF Etiology
Ischemic

15 (31)

Dilated

18 (28)

Non-ischemic

11 (23)

Chemotherapy

2 (4.2)

Idiopathic

1 (2.1)

Combined Ischemic(MI) & Non-ischemic(HTN)

1 (2.1)

NYHA Class
III

43 (90)

IV

3 (6.3)

Unknown

2 (4.2)

History of Angina
Yes

8 (17)

No

40 (83)

LVEF by echocardiogram

48

24 (9.1)

eGFR

46

71 (22.0)

Baseline SBP (mmHg)

48

127 (19)

Baseline DBP (mmHg)

48

78 (15)

Baseline HR (bpm)

48

86 (16)

Weight (kg)

47

92.8 (30.1)

IV Diuretics

41 (65)

Topical/Sublingual Nitroglycerin

7 (15)

* Two patients who left AMA within 24 h of presentation were included in this Table but excluded from subsequent
analyses for having only one data point.

3.2. Safety and Feasibility of 6MWT
Of the 46 total patients, 44 (95.7%) attempted a baseline 6MWT (Day 1). Of these, 21 (45.7%)
required at least one rest stop prior to the end of the 6-min walk period. Fewer patients attempted
a 6MWT on Day 2 (n = 38) and Day 3 (n = 28), largely due to early hospital discharge, while a minority
were unable to due to worsening clinical status. Importantly, only 4 patients refused to do a total of 5 of
the 154 individual 6MWTs in this study. Of the 32 patients who did not have a Day 5 6MWT, 27 were
due to hospital discharge at day 2 or 3, and only 5 were due to worsening clinical condition. No adverse
events were reported during the performance of the 6MWT. Four adverse events were reported in
4 patients during the 4 h period after the completion of the 6MWT—1 episode of paroxysmal atrial
fibrillation with onset ~12 min after the start of the 6MWT, 2 episodes of fever (16–10 min after 6MWT
start), and one episode of acute-on-chronic respiratory failure, 104 min after the start of the 6MWT.
No early withdrawal of patients occurred.
3.3. 6MWT Performance
At baseline (Day 1), the patients walked a mean of 137.3 ± 78 m. There was no correlation between
the Day 1 total distance walked or the distance to first stop with either LVEF or baseline SBP. On Day 2
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the same time did not correlate. Changes in the total distance and distance to first stop from Day 1 to
Day 3 exhibited a non-significant trend toward an inverse correlation with length of stay of the index
admission (r = −0.34, p = 0.09). Exploratory analyses for the relationship between the baseline 6MWT
and the probability of readmission (n = 9 patients) within 30 days suggest that a higher baseline 6MWT
was associated with a lower likelihood of readmission at 30 days (p = 0.06).
4. Discussion
The results of our pilot study suggests the following: (1) the performance of a 6MWT is feasible
for AHF patients, starting in the ED and continuing throughout hospitalization, as a minority of the
154 individual 6MWT’s were unable to be performed due to the worsening clinical status or patient
refusal; (2) the 6MWT distance improves as patients receive AHF therapy during hospitalization;
and, (3) the 6MWT distance is reproducible, as suggested by similar total distances when duplicate
6MWT testing occurred in the same subject within the same day. Six minute walk test performance
in these patients may be a function of the patient’s baseline status, a response to therapy, or both.
When compared to other critically ill HF patients, these AHF patients appear to have a lower baseline
6MWT distance (mean 182 m vs. 137 m respectively), and a smaller variability (SD of 140 m vs. 78 m,
respectively) [11]. At lower 6MWT distances, the primary limitation to ambulation may be the patient’s
physical status, and ambulatory distance may be less susceptible to verbal encouragement.
These pilot results suggest that the 6MWT could be utilized as a patient-centric endpoint in
AHF studies. Our study suggests that the 6MWT is feasible in AHF patients, as early as 2.1 h
after presentation (mean 10.8 h). Even patients who may be unable to walk at the baseline may
improve sufficiently over their hospitalization, enabling the subsequent 6MWT assessments to be
feasible. Thus, it would be important to include all of patients who indicate that they can walk at
baseline, even if when they are approached for enrollment they are too acutely ill to perform a 6MWT.
Similarly, when patient’s 6MWT time worsens or they become unable to perform the test, this could
be a sign of a lack of response to therapy. It is currently unclear if an absolute minimum distance
or a relative improvement over baseline 6MWT distance might be an appropriate predictor of other

J. Clin. Med. 2017, 6, 84

7 of 8

clinical outcomes. Larger studies are needed to determine whether the 6MWT distance is associated
with both short- and long-term outcomes. While we saw a trend toward an association between 6MWT
distance and 30-day events, we only had 9 patients who experienced 30-day readmission. As patients
received AHF therapy, their walk distance improved, suggesting that this could be an objective marker
to determine the optimal endpoints of therapy. If the 6MWT is found to be feasible in a larger cohort of
patients, and associated with clinical events, collaboration across hospitals, and between investigators
would be important to ensure its successful implementation.
Compared to the RED ROSE studies, where 1/3rd of patients either were unable or unwilling to
perform bedside stepping in place, the 6MWT was indeed feasible in our cohort of AHF patients [12].
While the reasons to perform an initial 6MWT are multifactorial, the baseline differences between
our study and RED ROSE are considerable. Our patients’ mean age was over 10 years younger,
with a much higher proportion of African Americans, and a 10 mmHg higher mean systolic blood
pressure. However, enrolling subjects in the ED setting supports the feasibility of performing functional
testing acutely. Our pilot study, albeit limited by the small number of patients, also highlights the
heterogeneity of the AHF population.
While we were limited by the sample size, we did not see an association between changes in
natriuretic peptide levels and 6MWT distance. There could be several reasons for this. Natriuretic
peptide levels have wide daily variation and are a lagging indicator when considering AHF resolution.
In stable outpatients with chronic HF, significant increases in BNP are not necessarily predictive of AHF.
Further, tailoring therapy based on natriuretic peptide levels have yielded mixed results. Similarly,
even significant increases in BNP levels in stable outpatients with HFrEF have not been predictive
of subsequent AHF [13]. There was significant variability in natriuretic peptide levels within each
patient in our study, and a decrease was not observed in all patients despite treatment and symptom
improvement. This has been seen in prior ED-based AHF studies where serial BNP levels were
measured. There was a mean change of 200–350 pg/mL in BNP during hospitalization, yet none of
these changes were helpful in predicting hospital LOS, 30-day readmission, or all-cause mortality [14].
Limitations: While our pilot study suggests that the 6MWT is feasible and reproducible in
AHF patients there were several limitations to consider. We enrolled a relatively small number of
patients who experienced few 30-day events. We also only enrolled HFrEF patients as this study was
designed to use the 6MWT in a subsequent clinical trial of HFrEF patients. There may be differences
in HFrEF and HFpEF patients related to the changes in their 6MWT as they receive AHF therapy.
Our clinical sites had a large proportion of younger, African American patients, so incorporating
a more demographically diverse population of patients to ensure generalizability would be important.
If illness severity or comorbidities differ in future studies than this may impact the proportion of
patients who could complete all of the administered tests. Our study’s small sample size limited our
ability to investigate this. The number of people who did a test on any given day is not the same as
the number of people who did all 3 days of tests, as different patients missed different days. We did
not track the reasons for the refusal to be in the study, and it would be good to quantify the impact of
disease severity on patient participation in future studies.
In summary, our pilot study suggests that the 6MWT is both feasible and safe in patients with AHF.
The majority of patients were able to perform this test, starting in the ED, and continuing throughout
hospitalization. A larger study is necessary to evaluate its utility in a more demographically diverse
population of patients, including those with preserved ejection fraction, and determine its relationship
to longer-term outcomes such as HF readmission and mortality.
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